west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "心肾综合征" 3 results
  • Effectiveness of Preoperative Recombinant Human Brain Natriuretic Peptide on Rheu-matic Valves Diseases with Cardiorenal Syndrome: A Randomized Controlled Trial

    ObjectiveTo investigate the efficacy of intravenous infusion of recombinant human brain natriuretic peptide in rheumatic heart valves patients with cardiorenal syndrome preoperatively, the function and operational results before and after treatment were compared. MethodsA randomized, single-blind, and controlled study was conducted in 60 patients characterized of rheumatic heart valves patients in our hospital from March 2012 through March 2015. There were 24 males and 36 females at average age of 52.1±8.9 years (ranged from 35-73 years). Their left ventricular ejection fraction was less than 40% and plasma creatinine was mildly or moderately raised. They were recruited into an experiment group and a control group by random digital table. The control group received continuous intravenous Dopamine and Nitroglycerin based anti-heart failure treatment (n=30). The experimental group received additional recombinant human brain natriuretic peptide for 48 hours without bolus (at a dose of 0.006 μg·kg-1·min-1, n=30). The levels of the biomarkers for cardiac and renal function between before and after treatment were compared. ResultsIn the experiment group, treatment with recombinant human brain natriuretic peptide for 48 hours had lower level of plasma NT-proBNP than the baseline level with a statistical difference (88.6±55.1 pg/ml vs. 55.0±47.6 pg/ml, P=0.014), lower level of high sensitivity creative reaction protein than the baseline level with a statistical difference (2.79±1.27 mg/l vs. 1.39±0.79 mg/l, P=0.000), more 24 hours urine output than the baseline level with a statistical difference (1 464.0±348.3 ml vs. 1 223.0±279.9 ml, P=0.005), lower level of serum cystatin-C than the baseline level with a statistical difference (0.25±0.14 mg/l vs. 0.08±0.07 mg/l, P=0.000), higher inotrope requirement within three days after operation (2.52±1.30 mg·kg-1·min-1 vs.3.36±1.15 mg·kg-1·min-1, P=0.011), less ICU stay days (4.5±1.2 days vs. 5.3±1.6 days, P=0.03). There were no statistical differences between the experiment group and the control group after treatment in cardiac function class, left ventricular ejection fraction, left ventricular end-diastolic diameter, creatinine, chest tube drainage volume, and intra-aortic balloon pumping use. ConclusionIntravenous injection of recombinant human brain natriuretic peptide in the patients with rheumatic valve disease combined with cardiorenal syndrome before operation can decrease systemic inflammation reaction and cardiac and renal function injury, and enhance operational recovery.

    Release date: Export PDF Favorites Scan
  • Diagnosis, treatment, and renal replacement therapy of cardio-renal syndrome

    Heart and kidney interact with each other. Cardio-renal syndrome (CRS) refers to conditions where acute or chronic dysfunction of either the heart or the kidney leads to dysfunction of the other. Conventional classification of CRS outlined five subgroups according to the clinical presentation. This review focused on the epidemiology, new bio- markers, drug management, and renal replacement therapy of type Ⅰ and type Ⅱ CRS, which emphasized the multi-discipline collaboration and individualized evaluation, in order to achieve goal-directed approach to renal replacement therapy.

    Release date:2018-07-27 09:54 Export PDF Favorites Scan
  • 体外膜肺氧合联合连续性肾脏替代治疗救治急性重症心肌炎合并心肾综合征一例

    Release date:2018-07-27 09:54 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content